FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3

J. B. Wilson, K. Yamamoto, A. S. Marriott, S. Hussain, P. Sung, Maureen Hoatlin, C. G. Mathew, M. Takata, L. H. Thompson, G. M. Kupfer, N. J. Jones

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Fanconi anemia (FA) is a human disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinks and other damages. Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group. Eight of the FA proteins, including FANCG, participate in a nuclear core complex that is required for the monoubiquitylation of FANCD2 and FANCI. FANCD2, like FANCD1/BRCA2, is not part of the core complex, and we previously showed direct BRCA2-FANCD2 interaction using yeast two-hybrid analysis. We now show in human and hamster cells that expression of FANCG protein, but not the other core complex proteins, is required for co-precipitation of BRCA2 and FANCD2. We also show that phosphorylation of FANCG serine 7 is required for its co-precipitation with BRCA2, XRCC3 and FANCD2, as well as the direct interaction of BRCA2-FANCD2. These results argue that FANCG has a role independent of the FA core complex, and we propose that phosphorylation of serine 7 is the signalling event required for forming a discrete complex comprising FANCD1/BRCA2-FANCD2-FANCG-XRCC3 (D1-D2-G-X3). Cells that fail to express either phospho-Ser7-FANCG, or full length BRCA2 protein, lack the interactions amongst the four component proteins. A role for D1-D2-G-X3 in homologous recombination repair (HRR) is supported by our finding that FANCG and the RAD51-paralog XRCC3 are epistatic for sensitivity to DNA crosslinking compounds in DT40 chicken cells. Our findings further define the intricate interface between FANC and HRR proteins in maintaining chromosome stability.

Original languageEnglish (US)
Pages (from-to)3641-3652
Number of pages12
JournalOncogene
Volume27
Issue number26
DOIs
StatePublished - Jun 12 2008

Fingerprint

Fanconi Anemia
Recombinational DNA Repair
Fanconi Anemia Complementation Group G Protein
Serine
Fanconi Anemia Complementation Group Proteins
BRCA2 Protein
Phosphorylation
Chromosomal Instability
Proteins
DNA
Cricetinae
Chickens
Yeasts
Genes
Neoplasms
Complementation Group D1 Fanconi Anemia

Keywords

  • ATR
  • DNA repair
  • Epistasis
  • Fanconi anemia
  • Interstrand crosslinks
  • RAD51 paralog
  • Replication restart

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Wilson, J. B., Yamamoto, K., Marriott, A. S., Hussain, S., Sung, P., Hoatlin, M., ... Jones, N. J. (2008). FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene, 27(26), 3641-3652. https://doi.org/10.1038/sj.onc.1211034

FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. / Wilson, J. B.; Yamamoto, K.; Marriott, A. S.; Hussain, S.; Sung, P.; Hoatlin, Maureen; Mathew, C. G.; Takata, M.; Thompson, L. H.; Kupfer, G. M.; Jones, N. J.

In: Oncogene, Vol. 27, No. 26, 12.06.2008, p. 3641-3652.

Research output: Contribution to journalArticle

Wilson, JB, Yamamoto, K, Marriott, AS, Hussain, S, Sung, P, Hoatlin, M, Mathew, CG, Takata, M, Thompson, LH, Kupfer, GM & Jones, NJ 2008, 'FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3', Oncogene, vol. 27, no. 26, pp. 3641-3652. https://doi.org/10.1038/sj.onc.1211034
Wilson, J. B. ; Yamamoto, K. ; Marriott, A. S. ; Hussain, S. ; Sung, P. ; Hoatlin, Maureen ; Mathew, C. G. ; Takata, M. ; Thompson, L. H. ; Kupfer, G. M. ; Jones, N. J. / FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. In: Oncogene. 2008 ; Vol. 27, No. 26. pp. 3641-3652.
@article{f3eb5877a4474674b59f7cf0e7970070,
title = "FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3",
abstract = "Fanconi anemia (FA) is a human disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinks and other damages. Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group. Eight of the FA proteins, including FANCG, participate in a nuclear core complex that is required for the monoubiquitylation of FANCD2 and FANCI. FANCD2, like FANCD1/BRCA2, is not part of the core complex, and we previously showed direct BRCA2-FANCD2 interaction using yeast two-hybrid analysis. We now show in human and hamster cells that expression of FANCG protein, but not the other core complex proteins, is required for co-precipitation of BRCA2 and FANCD2. We also show that phosphorylation of FANCG serine 7 is required for its co-precipitation with BRCA2, XRCC3 and FANCD2, as well as the direct interaction of BRCA2-FANCD2. These results argue that FANCG has a role independent of the FA core complex, and we propose that phosphorylation of serine 7 is the signalling event required for forming a discrete complex comprising FANCD1/BRCA2-FANCD2-FANCG-XRCC3 (D1-D2-G-X3). Cells that fail to express either phospho-Ser7-FANCG, or full length BRCA2 protein, lack the interactions amongst the four component proteins. A role for D1-D2-G-X3 in homologous recombination repair (HRR) is supported by our finding that FANCG and the RAD51-paralog XRCC3 are epistatic for sensitivity to DNA crosslinking compounds in DT40 chicken cells. Our findings further define the intricate interface between FANC and HRR proteins in maintaining chromosome stability.",
keywords = "ATR, DNA repair, Epistasis, Fanconi anemia, Interstrand crosslinks, RAD51 paralog, Replication restart",
author = "Wilson, {J. B.} and K. Yamamoto and Marriott, {A. S.} and S. Hussain and P. Sung and Maureen Hoatlin and Mathew, {C. G.} and M. Takata and Thompson, {L. H.} and Kupfer, {G. M.} and Jones, {N. J.}",
year = "2008",
month = "6",
day = "12",
doi = "10.1038/sj.onc.1211034",
language = "English (US)",
volume = "27",
pages = "3641--3652",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "26",

}

TY - JOUR

T1 - FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3

AU - Wilson, J. B.

AU - Yamamoto, K.

AU - Marriott, A. S.

AU - Hussain, S.

AU - Sung, P.

AU - Hoatlin, Maureen

AU - Mathew, C. G.

AU - Takata, M.

AU - Thompson, L. H.

AU - Kupfer, G. M.

AU - Jones, N. J.

PY - 2008/6/12

Y1 - 2008/6/12

N2 - Fanconi anemia (FA) is a human disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinks and other damages. Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group. Eight of the FA proteins, including FANCG, participate in a nuclear core complex that is required for the monoubiquitylation of FANCD2 and FANCI. FANCD2, like FANCD1/BRCA2, is not part of the core complex, and we previously showed direct BRCA2-FANCD2 interaction using yeast two-hybrid analysis. We now show in human and hamster cells that expression of FANCG protein, but not the other core complex proteins, is required for co-precipitation of BRCA2 and FANCD2. We also show that phosphorylation of FANCG serine 7 is required for its co-precipitation with BRCA2, XRCC3 and FANCD2, as well as the direct interaction of BRCA2-FANCD2. These results argue that FANCG has a role independent of the FA core complex, and we propose that phosphorylation of serine 7 is the signalling event required for forming a discrete complex comprising FANCD1/BRCA2-FANCD2-FANCG-XRCC3 (D1-D2-G-X3). Cells that fail to express either phospho-Ser7-FANCG, or full length BRCA2 protein, lack the interactions amongst the four component proteins. A role for D1-D2-G-X3 in homologous recombination repair (HRR) is supported by our finding that FANCG and the RAD51-paralog XRCC3 are epistatic for sensitivity to DNA crosslinking compounds in DT40 chicken cells. Our findings further define the intricate interface between FANC and HRR proteins in maintaining chromosome stability.

AB - Fanconi anemia (FA) is a human disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinks and other damages. Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group. Eight of the FA proteins, including FANCG, participate in a nuclear core complex that is required for the monoubiquitylation of FANCD2 and FANCI. FANCD2, like FANCD1/BRCA2, is not part of the core complex, and we previously showed direct BRCA2-FANCD2 interaction using yeast two-hybrid analysis. We now show in human and hamster cells that expression of FANCG protein, but not the other core complex proteins, is required for co-precipitation of BRCA2 and FANCD2. We also show that phosphorylation of FANCG serine 7 is required for its co-precipitation with BRCA2, XRCC3 and FANCD2, as well as the direct interaction of BRCA2-FANCD2. These results argue that FANCG has a role independent of the FA core complex, and we propose that phosphorylation of serine 7 is the signalling event required for forming a discrete complex comprising FANCD1/BRCA2-FANCD2-FANCG-XRCC3 (D1-D2-G-X3). Cells that fail to express either phospho-Ser7-FANCG, or full length BRCA2 protein, lack the interactions amongst the four component proteins. A role for D1-D2-G-X3 in homologous recombination repair (HRR) is supported by our finding that FANCG and the RAD51-paralog XRCC3 are epistatic for sensitivity to DNA crosslinking compounds in DT40 chicken cells. Our findings further define the intricate interface between FANC and HRR proteins in maintaining chromosome stability.

KW - ATR

KW - DNA repair

KW - Epistasis

KW - Fanconi anemia

KW - Interstrand crosslinks

KW - RAD51 paralog

KW - Replication restart

UR - http://www.scopus.com/inward/record.url?scp=45949110752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45949110752&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1211034

DO - 10.1038/sj.onc.1211034

M3 - Article

C2 - 18212739

AN - SCOPUS:45949110752

VL - 27

SP - 3641

EP - 3652

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 26

ER -